Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Stopped Medarex (supplier of BsAb) stopped study due to toxicities experienced at other sites on unrelated trials halting manufacturing of BsAb

Conditions

• Leukemia
• Lymphoma

Interventions

• BIOLOGICAL: bispecific antibody 4G7xH22
• BIOLOGICAL: sargramostim

Sponsor

Dartmouth-Hitchcock Medical Center

Collaborators

• [object Object]